13 May
Selecta Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update
SEL-399 (empty AAV8 capsid with ImmTOR) study on track with topline data expected in the fourth quarter of 2021 SEL-212 enrollment on track with topline data from DISSOLVE phase 3 program expected in second half of 2022 IND filing for IgA nephropathy program expected by the end of 2021 IND filing
06 May
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Business Update
WATERTOWN, Mass. , May 06, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences , Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to
29 Apr
Selecta Biosciences Announces Three Presentations at the Upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
WATERTOWN, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced three upcoming
29 Apr
Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program
– Methylmalonic Acidemia ( MMA) program to become wholly-owned by Selecta – – Selecta to postpone IND submission until at least the fourth quarter of 2021 – – Empty capsid (SEL-399) study remains on track – WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C.
05 Apr
Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference
WATERTOWN, Mass. , April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
11 Mar
Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
-   First-in-human dose-escalation study to evaluate ability of ImmTOR™  to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 - -   Methylmalonic acidemia   (MMA) gene therapy program in collaboration with AskBio expected to enter the clinic in
04 Mar
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
WATERTOWN, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to
01 Mar
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
WATERTOWN, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
24 Feb
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector - - ImmTOR shown to increase hepatic vector copy numbers and transgene mRNA expression - - Replicated findings supporting ImmTOR’s ability to block the formation of
17 Feb
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy – WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc.